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Background: Nasopharyngeal colonisation by S. pneumoniae is a prerequisite for invasive pneumococcal
infections. Influenza co-infection leads to increased susceptibility to secondary pneumonia and mortality
during influenza epidemics. Increased bacterial load and impaired immune responses to pneumococcus
caused by influenza play a role in this increased susceptibility. Using an Experimental Human Challenge
Model and influenza vaccines, we examined symptoms experienced by healthy adults during nasal co-
infection with S. pneumoniae and live attenuated influenza virus.
Methods: Randomised, blinded administration of Live Attenuated Influenza Vaccine (LAIV) or Tetravalent
Inactivated Influenza Vaccine (TIV) either preceded bacterial inoculation or followed it, separated by a 3-
day interval. The presence and density of S. pneumoniae was determined from nasal washes. Participants
completed a symptom questionnaire from the first intervention until 6 days post second intervention.
Results: The timing and type of influenza vaccination and presence of S. pneumoniae in the nasopharynx
significantly affected symptom reporting. In the study where influenza vaccination preceded bacterial
inoculation: nasal symptoms were less common in the LAIV group than the TIV group (OR 0.57,
p < 0.01); with colonisation status only affecting the TIV group where more symptoms were reported
by colonised participants compared to non-colonised participants following inoculation (n = 12/23
[52.17%] vs n = 13/38 [34.21%], respectively; p < 0.05). In the study where influenza vaccination followed
bacterial inoculation: no difference was seen in the symptoms reported between the LAIV and TIV groups
following inoculation and subsequent vaccination; and symptoms were unaffected by colonisation
status.
Conclusion: Symptoms experienced during live viral vaccination and bacterial co-infection in the
nasopharynx are directly affected by the precedence of the pathogen acquisition. Symptoms were directly
affected by nasal pneumococcal colonisation but only when TIV was given prior to bacterial exposure.
 2020 Published by Elsevier Ltd.1. Introduction
Nasopharyngeal colonisation by S. pneumoniae is a prerequisite
for pneumonia, meningitis, sinusitis and otitis media [1,2]. Reports
suggest that point prevalence of colonisation is 21–52% and 6.5–8%
in children and adults, respectively [3–5], although it is uncertain if
these natural colonisation events are associated with symptoms [4].It has been suggested that nasopharyngeal symptoms are related
to the viral co-infection and not bacterial colonisation [6]. In chil-
dren, pneumococcal colonisation densities are increased by viral
infection, irrespective of whether symptoms are present or not
[6]. Furthermore, Live Attenuated Influenza Vaccine (LAIV) (used
annually in children in the UK, USA and other countries) is com-
monly associated with runny nose and nasal congestion in all ages
groups, fever in children, and sore throat in adults [7]. In adults,
nasopharyngeal colonisation with S. pneumoniae is considered an
asymptomatic event [8–11], although no studies have examined
symptoms in the context of viral/bacterial co-infection particularly
in adults.eumo-
2 C. Hales et al. / Vaccine xxx (xxxx) xxxInfluenza co-infection can lead to secondary pneumonia, which
frequently drives mortality during influenza epidemics [12–14].
LAIV is safe and effective [15,16], but it has been reported that it
can also increase rates and density of pneumococcal colonisation
[17,18] leading to a theoretical risk of increased pneumococcal
transmission to susceptible groups [19].
Using Experimental Human Pneumococcal Challenge (EHPC),
we have previously described the interaction of pneumococcus
and viral pathogens and host immune responses [18,20,21]. Using
this model, we now investigated the symptoms experienced by
healthy adults during nasal co-infection with influenza and S.
pneumoniae, and examine the importance of order in which both
pathogens are encountered.2. Materials and methods
2.1. Trial design and vaccination
This single-centred, double-blinded, randomised, controlled
trial involved two sequentially recruited cohorts. The ‘antecedent’
cohort (2015/16) received influenza vaccine 3 days prior to nasal
inoculation with Streptococcus pneumoniae. The ‘concurrent’ study
(2016/17) reversed this order (pneumococcal inoculation was per-
formed 3 days before influenza vaccine administration). Full cohort
details have been previously described [18]. The study was
EudraCT registered (2014-004634-26).
2.2. Sampling, recruitment
We recruited healthy, non-smoking adults, aged 18–50 years
old. Exclusion criteria were: influenza or pneumococcal vaccina-
tion; clinically confirmed pneumococcal disease in the preceding
two years; close contact with ‘high-risk’ individuals (children
under 5 years, immunosuppressed, elderly); current febrile illness;
recent or current use of antibiotics or immune-modulating medi-
cation; pregnancy.
2.3. Procedure
The study was conducted as previously described [18]. Briefly,
participants were randomised to receive either nasal LAIV (Fluenz
Tetra or FluMist Tetra, AstraZeneca, UK; used interchangeably due
to procurement shortages; both are pharmaceutically identical but
have different packaging and labelling) with an intramuscular pla-
cebo (0.5 mL normal saline), or a nasal placebo (0.2 mL normal sal-
ine) with an intramuscular Tetravalent Inactivated Influenza
Vaccination (TIV) (Fluarix Tetra, GlaxoSmithKline, UK). Participants
were blindfolded during administration, with blinding maintained
until completion of primary analysis. Experimental pneumococcal
challenge comprised 80,000 colony forming-units (CFU) of
penicillin-susceptible, mid-log phase grown Streptococcus pneumo-
niae serotype 6B (strain BHN418) in 0.1 mL saline instilled by lab-
oratory pipette into each nostril [22].
2.4. Data collection
Pneumococcal colonisation status was determined by conven-
tional culture and quantified by serial dilution of nasal washes
[22–25]. Participants completed a daily symptom questionnaire
from the day of vaccination until 6 days post inoculation (an-
tecedent cohort, total of 9 days) or from the day of inoculation until
3 days post vaccination (concurrent cohort, total of 6 days). Partic-
ipants were unaware of their colonisation status until after symp-
tom log data had been completed and returned. Symptoms were
assessed using a modified Likert score for severity [26]. In the ante-Please cite this article as: C. Hales, S. P. Jochems, R. Robinson et al., Symptoms
coccal colonisation of the nasopharynx, Vaccine, https://doi.org/10.1016/j.vacccedent cohort 10 symptoms were examined (5 nasal and 5 non-
nasal symptoms) on an 7-point severity scale. Based on participant
feedback, the questionnaire was modified for the concurrent
cohort to improve usability. The scoring system for both studies
was aligned for analysis. A score of 2 (no symptoms or occasional
limited episode) was considered ‘asymptomatic’ and a score of 3
(mild steady symptoms to severe hard to tolerate symptoms) was
considered ‘symptomatic’. Symptoms were categorised as indi-
cated to reduce the impact of participants reporting a symptom
which was an isolated episode of short duration that would not
fit with known symptomology patterns of respiratory infection
[27].
2.5. Data analysis
Individuals were ‘colonised’ if S. pneumoniae serotype 6B was
detected by nasal wash culture at any time point following exper-
imental challenge in the study period. Individuals who were natu-
rally colonised with any serotype of S. pneumoniae at baseline were
excluded from the data analysis. Generalised Estimating Equation
(GEE) was used to analyse symptoms with binomial distribution
for symptom outcomes (0 = No symptoms, 1 = symptomatic) and
logit link function, taking into account repeated measurements in
symptoms. To assess the treatment effect on symptoms, the GEE
model has treatment (LAIV, TIV), time (<=3 days, >=4 days), inter-
action between treatment and time as study variables, partici-
pants’ age and gender as covariates. Difference in log odds of
having a symptomatic outcome between LAIV and TIV at each time
point was derived from the GEE model. To assess the difference in
symptoms between colonisation status, the GEE model has coloni-
sation status (positive, negative), time (<=3 days, >=4 days), inter-
action between colonisation status and time as study variables,
participants’ age and gender as covariates. Difference in log odds
of having a symptomatic outcome between positive and negative
colonisation status at each time point was derived from the GEE
model. All analysis was based on the intention to treat basis. Statis-
tical analyses were performed using SAS 9.4 (SAS Institute, Cary,
NC, USA); a two-tailed P value < 0.05 was considered statistically
significant.
2.6. Safety and ethics
Adverse events (including symptoms judged to be severe by the
clinician), and use of standby antibiotics were universally
recorded. No serious adverse events were reported however, 18
participants (antecendent study n = 8; concurrent study n = 10)
were reviewed by a clinician for symptoms requiring clinical inves-
tigation at any time point in the study. Of the 18 triggered clinical
examinations, 6 occurred during the timeframe of daily symptom
reporting (see Suppl Table 1). The study was approved by the Liver-
pool East NHS Research Committee (14-NW-1460) and the Medici-
nes and Healthcare products Regulatory Agency (EudraCT; Protocol
2014-00446334-26). All participants gave informed written
consent.3. Main results
3.1. Antecedent study
3.1.1. Nasal and non-nasal symptoms increased following TIV
vaccination compared to LAIV vaccination
Participants were first vaccinated with influenza, and inocu-
lated with S. pneumoniae 3 days later. 117 participants completed
the primary study end points and 114 returned their symptom log
questionnaires for data analysis (LAIV n = 53, TIV n = 61). Asassociated with influenza vaccination and experimental human pneumo-
ine.2020.01.070
C. Hales et al. / Vaccine xxx (xxxx) xxx 3previously described, demographics were similar in both groups [18].
47 participants (41%) became experimentally colonised; 45.3%
(n = 24) and 37.7% (n = 23) in the LAIV and TIV groups, respectively.
Overall 34.0% (18/53) participants in the LAIV group and 49.2%
(30/61) participants in the TIV group reported one or more
nasal or non-nasal symptoms, or both, at any time point in
the 9 days following vaccination. Statistical difference between
these two groups was seen for most nasal symptoms with less
symptoms reported in the LAIV group (Fig. 1; Fig. 2 right panel;
Suppl Table 2).
3.1.2. Nasal and non-nasal symptoms following TIV vaccination are
observed after challenge with S. pneumoniae
We investigated whether influenza vaccination led to symp-
toms in healthy adults. Apart from post nasal drip there wasFig. 1. Symptom reporting in the antecedent cohort. The percentage of participants repor
colonised (n = 38, black circles and solid line), TIV – Spn colonised (n = 23, black triangles a
Spn colonised (n = 24, grey triangles and dashed line). Day of vaccination and Spn inocu
Please cite this article as: C. Hales, S. P. Jochems, R. Robinson et al., Symptoms
coccal colonisation of the nasopharynx, Vaccine, https://doi.org/10.1016/j.vaccno statistical difference in the reporting of symptoms (LAIV
23%; n = 12/53 vs TIV 25%; n = 15/61) in the 3 days following
vaccination in either group (Fig. 1; Fig. 2 left panel; Suppl
Table 2). Following inoculation, reporting of one or more symp-
toms were less in the LAIV group with 19% (n = 10/53) compared
to 41% (n = 25/61) in the TIV group. Nasal symptoms were over-
all less common in the LAIV group (OR 0.57, p < 0.05). Specifi-
cally, symptoms of runny nose, congestion and post nasal drip
were all significantly less common in the LAIV group (OR 0.33;
0.55; 0.19, respectively; p < 0.05) (Fig. 1; Fig. 2 centre panel;
Suppl Table 2). Non-nasal symptoms were also reported less in
the LAIV group following inoculation; specifically overall assess-
ment, cough and sore throat (OR 0.22, OR 0.47 and OR 0.26
respectively; p < 0.05 in all cases) (Fig. 1; Fig. 2 centre panel;
Suppl Table 2).ting symptoms per day for each of the collected symptoms per group: TIV – Spn non-
nd dashed line), LAIV – Spn non-colonised (n = 29, grey circles and solid line), LAIV –
lation are depicted. Spn = S. pneumoniae.
associated with influenza vaccination and experimental human pneumo-
ine.2020.01.070
Fig. 2. Antecedent study- Symptoms reported by participants receiving nasal LAIV (n = 53) compared with those receiving intramuscular TIV (n = 61). Timepoints are split up
as until day of Spn inoculation, post Spn inoculation or all timepoints combined. All subjects are included regardless of ultimate Spn colonisation status. Bars represent log10
transformed odds ratios with 95% confidence intervals. Asterisks denote p < 0.05 i.e. a statistically significant difference in the rate of reporting between the two arms of the
trial. Odds ratios are derived from GEE model analysis (see methods), and are presented as those occurring early (left panel, at or before 3 days after vaccination and pre Spn
inoculation), or late (centre panel, 4 or more days after vaccination and Spn inoculation), or combined throughout the period of reporting (right panel). Spn = S. pneumoniae.
4 C. Hales et al. / Vaccine xxx (xxxx) xxx3.1.3. Successful establishment of S. pneumoniae colonisation rather
than challenge alone is associated with increased symptoms following
TIV vaccination
We investigated whether colonisation status led to symptoms
following vaccination. In the TIV group, more nasal and non-
nasal symptoms were reported by colonised participants (52%;
n = 12/23) compared to non-colonised participants (34%;
n = 13/38) following inoculation (>=4 days) with statistical signif-
icance seen for all reported nasal symptoms, sore throat, cough and
overall assessment (Fig. 1; Fig. 3 lower centre panel; Suppl Table 3).
In contrast, in the LAIV group, statistical difference was seen for
only 2 symptoms. These were total nasal symptoms which were
reduced and headache which was increased in colonised partici-
pants after inoculation (OR 0.17 and OR 22.17; p < 0.005) (Fig. 1;
Fig. 3 upper centre panel; Suppl Table 4). Fewer nasal and non-
nasal symptoms were reported by colonised participants who
received LAIV prior to inoculation (38%; n = 9/24) compared to
those participants who received TIV (52%; n = 12/23) (Fig. 1;
Fig. 4 lower centre panel; Suppl Table 5). This statistical difference
was observed mainly in nasal symptom reporting and for sore
throat, cough and overall assessment (p < 0.05). Similarly, fewer
symptoms were observed in non-colonised participants who
received LAIV prior to inoculation (31%; n = 9/29) compared to
those participants who received TIV (47%; n = 18/38). However,
statistical significance was only seen in non-nasal symptoms; sore
throat, headache and overall assessment (p < 0.05) (Fig. 1; Fig. 4
upper centre panel; Suppl Table 6).
In summary, similar rates of symptoms were reported following
vaccination with either LAIV or TIV vaccinations. However, oncePlease cite this article as: C. Hales, S. P. Jochems, R. Robinson et al., Symptoms
coccal colonisation of the nasopharynx, Vaccine, https://doi.org/10.1016/j.vaccparticipants were inoculated with S. pneumoniae statistical differ-
ences were seen in the reporting of symptoms between these
two groups. Most noticeable was the reduction in symptoms
reported in the LAIV group, regardless of colonisation status, com-
pared to the TIV group.
3.2. Concurrent study
3.2.1. LAIV and TIV do not differentially induce symptoms when
administered after S. pneumoniae
Participants were first inoculated with S. pneumoniae and then
received influenza vaccines 3 days later. 163 participants com-
pleted the primary study end points and 157 returned their symp-
tom log questionnaires for data analysis (LAIV n = 70, TIV n = 87).
As reported, similar demographics were observed in both groups
[18]. In total, 79 participants (50%) became experimentally colo-
nised with both groups having similar colonisation rates (LAIV
50% and TIV 51%). Overall 31% (22/70) participants in the LAIV
group and 32% (28/87) participants in the TIV group reported
one or more nasal or non-nasal symptoms, or both, at any time
point in the 6 days following inoculation. Runny nose (LAIV 11%,
n = 8/70; TIV 13%, n = 11/87), congestion (LAIV 9%, n = 6/70; TIV
18%, n = 16/87) and sore throat (LAIV 11%, n = 8/70; TIV 14%,
n = 12/87) were the most frequently reported symptoms in both
groups. No statistical difference was seen in the reporting of symp-
toms across both groups (Fig. 5; Suppl Table 7).
We investigated whether inoculation with S. pneumoniae led to
symptoms in healthy adults in the absence of any influenza vaccine
in the three days prior to the administration of LAIV or TIV. Atassociated with influenza vaccination and experimental human pneumo-
ine.2020.01.070
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GEE model analysis of symptoms: Colonisation Positive vs. Negative (reference−Negative)
Fig. 3. Antecedent Study- Symptoms reported by participants who had become colonised with Streptococcus pneumoniae (LAIV n = 24; TIV n = 23) compared with those who
did not (LAIV n = 29; TIV n = 38). Timepoints are split up as until day of Spn inoculation, post Spn inoculation or all timepoints combined. Bars represent log10 transformed
odds ratios with 95% confidence intervals. Asterisks denote p < 0.05 i.e. a statistically significant difference in the rate of reporting between colonised (positive) and non-
colonised (negative) individuals. Odds ratios are derived from GEE model analysis (see methods), and are presented as those occurring early (left panels, at or before 3 days
after vaccination and pre Spn inoculation), or late (centre panels, 4 or more days after vaccination and following Spn inoculation), or combined throughout the period of
reporting (right panels). Reported symptoms are subdivided by their vaccination group: LAIV nasal spray (upper panels); TIV intramuscular (lower panels). Spn = S.
pneumoniae.
C. Hales et al. / Vaccine xxx (xxxx) xxx 5baseline (prior to inoculation) 10% (n = 7/10) in the LAIV group and
3% (n = 3/87) in the TIV group reported one or more nasal or non-
nasal symptoms, or both. In the 3 days following inoculation sim-
ilar rates of reported symptoms were noted across both groups
(LAIV 21%, n = 15/70, TIV 22%, n = 19/87). Despite differences at
baseline there was no statistical difference in the reporting of
symptoms between the two groups (Fig. 5; Suppl Table 7). Follow-
ing vaccination, three days after inoculation, symptoms remained
at similar rates in both the LAIV group with 26% (n = 18/70) and
25% (n = 22/87) in the TIV group; no statistical difference was seen
in the number of participants reporting symptoms following vacci-
nation in either group (Fig. 5; Suppl Table 7).3.2.2. Nasal and non-nasal symptoms were the same between the LAIV
and TIV group regardless of colonisation status
We investigated whether colonisation status led to symptoms
following inoculation. There was no statistical difference in the
symptoms reported by colonised participants by GEE (LAIV 37%,
n = 13/35; TIV 39%, n = 17/44) compared to non-colonised partic-
ipants (LAIV 26%, n = 9/35; TIV 26%, n = 11/43) following inocula-
tion in either group (Fig. 5; suppl tables 8 and 9). Similarly, there
was no statistical difference seen in the symptoms reported by
colonised participants between the LAIV and TIV groups (Fig. 5;
Suppl Table 10).
In summary, similar rates of symptom reporting was found in
both groups following inoculation with S. pneumoniae and subse-
quently in the 3 days after receiving an influenza vaccination.Please cite this article as: C. Hales, S. P. Jochems, R. Robinson et al., Symptoms
coccal colonisation of the nasopharynx, Vaccine, https://doi.org/10.1016/j.vaccColonisation status of the participant did not affect the reporting
of symptoms.4. Discussion
This is the first study to evaluate symptoms associated with live
attentuated influenza vaccine and controlled pneumococcal
colonisation. The timing and route of influenza vaccination, and
the presence of S. pneumoniae in the nasopharynx, had a significant
effect on symptoms in adults. Reported symptoms following
S. pneumoniae inoculation were consistent with those reported in
previous EHPC studies [11]. However, higher incidences of nasal
and non-nasal symptoms were reported by Trimble et al. [11]
due to a lower threshold of symptom reporting. The most com-
monly reported symptoms following vaccination were runny nose,
congestion, and sore throat; reflecting published data following
LAIV administration [7]. However, we found much lower inci-
dences of nasal symptoms in our study compared to previously
published rates in adults following LAIV administration (20% vs
44%, respectively) [7]. Reasons for these differences is unclear but
might relate to the timeframe of symptom data collection, year
to year variation in vaccine replication efficiency, the different data
collection methods and thresholds for reporting symptoms.
Our results demonstrate that LAIV administration prior to pneu-
mococcal inoculation significantly reduces nasal and non-nasal
symptoms compared to TIV. Additionally, less symptoms were
seen in the LAIV group compared to the TIV group after inoculationassociated with influenza vaccination and experimental human pneumo-
ine.2020.01.070
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Fig. 4. Antecedent study- Symptoms reported by participants receiving nasal LAIV (colonised/positive n = 24; non colonised/negative n = 29) compared with those receiving
intramuscular TIV (colonised/positive n = 23; non colonised/negative n = 38). Timepoints are split up as until day of Spn inoculation, post Spn inoculation or all timepoints
combined. Bars represent log10 transformed odds ratios with 95% confidence intervals. Asterisks denote p < 0.05 i.e. a statistically significant difference in the rate of reporting
between the two arms of the trial. Odds ratios are derived from GEE model analysis (see methods), and are presented as those occurring early (left panels, at or before 3 days
after vaccination and pre Spn inoculation), or late (centre panels, 4 or more days after vaccination and following Spn inoculation), or combined throughout the period of
reporting (right panels). Reported symptoms are subdivided by their colonisation status: negative (no colonisation, upper panels); positive (colonised, lower panels).
Spn = S. pneumoniae.
6 C. Hales et al. / Vaccine xxx (xxxx) xxxdespite similar symptom rates between the two groups following
vaccination. For the concurrent study, there was no difference seen
in symptom rates following inoculation or vaccination in either
vaccine group. The reasons for these differences are unclear,
although we have previously observed from the antecedent study
that LAIV induces a strong pro-inflammatory response in the nose,
but impairs nasal neutrophil responses to S. pneumoniae colonisa-
tion compared to TIV vaccinated participants [20]. During acute
respiratory viral infections neutrophils have been shown to posi-
tively correlate with nasal symptom severity [28] and could
explain why fewer nasal symptoms are reported in the LAIV vacci-
nation group.
We found evidence that colonisation status led to significant
differences in symptoms between the LAIV and TIV groups across
both studies. In the antecedent study, TIV treated colonised adults
had higher nasal symptom reporting compared to TIV non-
colonised adults. However, in the LAIV group there was no differ-
ence seen in symptoms reported between colonised and non-
colonised adults either before or after inoculation. Likewise, fewer
nasal symptoms were seen in LAIV colonised adults compared to
TIV colonised adults. In the concurrent study, colonisation status
did not affect symptoms between the two vaccination groups. This
suggests that TIV potentiates symptoms following colonisation. In
the antecedent study, post nasal drip and cough were only
increased pre but not post S. pneumoniae exposure. One possibility
is that these are transient effects of vaccination, which can bePlease cite this article as: C. Hales, S. P. Jochems, R. Robinson et al., Symptoms
coccal colonisation of the nasopharynx, Vaccine, https://doi.org/10.1016/j.vaccobserved in the first days following vaccine administration, but
not at later points.
Co-colonisation (with LAIV and S. pneumoniae) in healthy adults
led to a transient increase in acquisition at Day 2 following bacte-
rial challenge in those who had previously received LAIV (33/55
[60.0%] vs 25/62 [40.3%] in TIV, p = 0.03). Bacterial carriage densi-
ties were increased approximately 10-fold by Day 9 in the LAIV
recipients [18]. We have now shown that co-infection and its asso-
ciated increase in pneumococcal density did not correlate with
symptom reporting, consistent with other research in adults [11].
Conversely, in children, it has been found that being colonised with
S. pneumoniae at the time of LAIV administration causes a 6-fold
increase in bacterial densities at Day 28, with symptoms of rhinitis
positively associated with pneumococcal density [17].
We used an adapted validated respiratory symptom tool
[26,29]. Recall bias was limited by contemporaneous completion
of a symptom log. Using this novel human co-infection challenge
model, we were able to determine the exact day of pneumococcal
exposure in relation to the influenza vaccination and the timing
and duration of pneumococcal colonisation. The main limitations
were the use of two slightly different questionnaires between the
antecedent and concurrent studies: we were therefore able to com-
pare directly the presence of symptoms, but not severity. Secondly,
there was no control group for mock-vaccinations or inoculations
as it was assumed that in the absence of a vaccination or being
non-colonised was an asymptomatic process [11], and we did notassociated with influenza vaccination and experimental human pneumo-
ine.2020.01.070
Fig. 5. Symptom reporting in the concurrent cohort. The percentage of participants reporting symptoms per day for each of the collected symptoms per group: TIV – Spn non-
colonised (n = 43, black circles and solid line), TIV – Spn colonised (n = 44, black triangles and dashed line), LAIV – Spn non-colonised (n = 35, grey circles and solid line), LAIV –
Spn colonised (n = 35, grey triangles and dashed line). Day of vaccination and Spn inoculation are depicted. Spn = S. pneumoniae.
C. Hales et al. / Vaccine xxx (xxxx) xxx 7anticipate topical effects of TIV administration. A control group for
mock-vaccinations or inoculations would have helped to further
dissect the relative contributions of the vaccination and inocula-
tion to symptoms.
We hypothesised that nasally administered LAIV would pro-
duce more symptoms than intramuscular TIV in healthy adults.
However, the results, unexpectedly, demonstrated that TIV in par-
ticular when followed by S. pneumoniae colonisation caused more
symptoms in adults than LAIV. These results were biologically rel-
evant as we scored symptoms on a scale, where a score of 2 (no
symptoms or occasional limited episode) was considered ‘asymp-
tomatic’ and a score of 3 (mild steady symptoms to severe hard
to tolerate symptoms) was considered ‘symptomatic’. By definition
what we defined as symptomatic was therefore noticeable at least
by the participants.Please cite this article as: C. Hales, S. P. Jochems, R. Robinson et al., Symptoms
coccal colonisation of the nasopharynx, Vaccine, https://doi.org/10.1016/j.vaccThe authors acknowledge that these results are counter-
intuitive based on the adverse events data collected following
vaccination with LAIV versus TIV, previously [30]. However, we
performed two randomised double-blinded placebo-controlled
clinical trials with 271 participants who completed symptom
questionnaires allowing us to interrogate the effects of vaccina-
tion in the setting of existing or new S. pneumoniae colonisation.
The differences between groups were not apparent prior to the
intervention, indicating these are true biological effects. What is
important to note is that symptoms were driven not just by the
vaccine alone, but strongly associated with the S. pneuomoniae
colonisation afterwards. We demonstrated that LAIV impaired
neutrophilic degranulation upon S. pneumoniae colonisation [20],
and it is for example possible that this, or another immune mech-
anism that was altered by LAIV, led to the differences in symp-associated with influenza vaccination and experimental human pneumo-
ine.2020.01.070
8 C. Hales et al. / Vaccine xxx (xxxx) xxxtoms. We believe these results highlight that the environment
and microbiota can therefore affect symptomology differentially
following vaccination with attenuated and inactivated vaccines.
Importantly, the order of vaccination had an impact of symptom
reporting, as it did on microbiological endpoints (S. pneumoniae
colonisation) in the trial [18].5. Conclusion
This is the first controlled challenge study in humans to directly
assess the symptomology of a respiratory live viral vaccine during
co-infection with a human pathogen. Our study demonstrates that
symptoms experienced during live viral vaccination and bacterial
co-infection in the nasopharynx are directly affected by the prece-
dence of the pathogen acquisition. The mechanism by which LAIV
and TIV influence the symptoms in adults remains undetermined.
Further research should target our understanding of the immuno-
logical processes that underpin the symptomology of LAIV and TIV
administration prior to or following the acquisition of S. pneumo-
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